Pulmonx Business Summary

Pulmonx Corp (LUNG) is a commercial-stage medical technology leader specializing in minimally invasive treatments for severe emphysema, a form of COPD. The company generates revenue primarily through the direct sale and distribution of its flagship Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the StratX Lung Analysis Platform to hospitals and clinics globally. Its business is segmented into U.S. and International markets, with the U.S. serving as the primary revenue driver while international expansion in EMEA and APAC provides significant growth momentum. Pulmonx maintains a dominant market position as the pioneer of bronchoscopic lung volume reduction (BLVR), competing against Spiration (Olympus), Broncus Medical, TriSalus Life Sciences, and KORU Medical Systems. Unlike its competitors, Pulmonx leverages a comprehensive "predict-and-treat" solution that combines physiological assessment with therapeutic intervention, establishing it as the clinical standard of care in the interventional pulmonology space. The company was founded by Mike Connolly and is currently led by President and CEO Glen French, a medical device veteran with over 30 years of experience who previously held leadership roles at Boston Scientific and co-founded Asthmatx. Supporting the executive suite are Derrick Sung, Ph.D., who serves as both Chief Operating Officer and Chief Financial Officer following his tenure at iRhythm Technologies, and Sri Radhakrishnan, the Chief Science and Technology Officer. The leadership team is overseen by a robust Board of Directors chaired by Dana G. Mead, Jr., a former partner at Kleiner Perkins, and includes Thomas W. Burns, the CEO of Glaukos Corporation. Pulmonx is backed by notable institutional investors, including Primecap Management Company, Ally Bridge Group, and HealthCap, reflecting strong confidence in the company’s clinical data and commercial scalability.